We are thrilled to announce that Exploration of Targeted Anti-tumor Therapy (ETAT) has achieved a CiteScore of 3.1 for 2024, as reported by Scopus. This marks a significant increase from the 2023 CiteScore of 2.8 and the 2022 CiteScore of 1.7, reflecting the journal's consistent growth in academic recognition and citations within the oncology field.

Additionally, the latest CiteScoreTracker score has reached a new high of 3.5, further underscoring ETAT's growing impact and visibility among researchers worldwide. These accomplishments are a testament to the collective efforts of our authors, reviewers, guest editors, and editorial board members, whose dedication and trust have been instrumental in shaping this progress.

At ETAT, we remain committed to upholding rigorous academic standards while continuously optimizing our peer-review process to ensure a high quality and efficient publishing experience. We warmly invite researchers globally to submit their work, propose special issues, and engage with our journal as we strive to advance the field of cancer research together.

For more information, please visit: https://www.scopus.com/sourceid/21101088220.

Let us continue to achieve new milestones collaboratively.